Share on StockTwits

Harvard Bioscience (NASDAQ:HBIO) CFO Robert E. Gagnon acquired 5,000 shares of the company’s stock on the open market in a transaction that occurred on Monday, June 16th. The shares were purchased at an average price of $3.86 per share, with a total value of $19,300.00. Following the transaction, the chief financial officer now directly owns 5,000 shares in the company, valued at approximately $19,300. The acquisition was disclosed in a legal filing with the SEC, which is available at this link.

Harvard Bioscience (NASDAQ:HBIO) opened at 3.90 on Wednesday. Harvard Bioscience has a 52-week low of $3.4951 and a 52-week high of $5.15. The stock’s 50-day moving average is $4.11 and its 200-day moving average is $4.45. The company’s market cap is $124.6 million.

Harvard Bioscience (NASDAQ:HBIO) last issued its quarterly earnings data on Thursday, May 1st. The company reported $0.05 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.03 by $0.02. The company had revenue of $25.90 million for the quarter, compared to the consensus estimate of $26.10 million. On average, analysts predict that Harvard Bioscience will post $0.15 earnings per share for the current fiscal year.

Harvard Bioscience, Inc is a global developer, manufacturer and marketer of a range of specialized products, apparatus and scientific instruments, used to advance life science research at pharmaceutical and biotechnology companies, universities and government laboratories worldwide.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.